Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer

@article{Dellis2018ApalutamideTE,
  title={Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer},
  author={Athanasios E Dellis and Athanasios Papatsoris},
  journal={Expert Opinion on Investigational Drugs},
  year={2018},
  volume={27},
  pages={553 - 559}
}
ABSTRACT Introduction: Prostate cancer (PCa) is the most common cancer in elderly males. Androgen deprivation therapy (ADT) is still the cornerstone of initial treatment; however, the vast majority of patients develop castration-resistant prostate cancer (CRPC). Several studies with numerous androgen receptor (AR)-directed agents have emerged since the approval of abiraterone acetate and enzalutamide. One of these agents is apalutamide, which seems to be a promising AR antagonist for the… 
The development of apalutamide for the treatment of prostate cancer
TLDR
Apalutamide has become a relevant therapy for patients with nmCRPC and mHSPC for its benefit in delaying metastasis in addition to its improvement of overall survival, without compromising the quality of life.
An up-to-date evaluation of darolutamide for the treatment of prostate cancer
TLDR
Darolutamide is considered to have the lowest probability for adverse events (AEs) compared to apalutamide and enzalUTamide, and this is the main reason that makes darlutamide exceptional in terms of safety and efficacy compared to other drugs in this category.
Perspectives on the current and emerging chemical androgen receptor antagonists for the treatment of prostate cancer
TLDR
Currently used and emerging AR antagonists for the treatment of castration resistant prostate cancer and the challenge will be to determine an AR antagonist with the best combination of outcome and tolerability.
Pharmacotherapeutic strategies for castrate-resistant prostate cancer
TLDR
No differences in the overall survival has been observed between sequences starting with docetaxel versus AA/ENZ, and the AA-to-ENZ sequence appeared to be more favorable than the ENZ- to-AA regarding progression-free survival but not overall survival.
Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond
TLDR
A concise overview of the clinical development, use and effectiveness of enzalutamide in the treatment of advanced prostate cancer is provided, translational research addressing enzalUTamide response vs resistance is described and novel potential treatment strategies in the enzyme-resistant setting are highlighted.
Apalutamide: a better option for the treatment of non-metastatic castration resistant prostatic carcinoma
TLDR
Apalutamide is used in conjunction with castration, either via bilateral orchiectomy or gonadotropin-releasing hormone analogue (GnRH analogue) therapy, as a method of androgen deprivation therapy in the treatment of non-metastatic castration-resistant prostate cancer (NM-CRPC).
Molecules targeting the androgen receptor (AR) signaling axis beyond the AR‐Ligand binding domain
TLDR
This review aims to present and comprehensively discuss molecules that affect AR signaling through direct or indirect interactions with the AR‐TAD or the DBD, and highlights the significant in vitro and in vivo data found for each compound and the apparent limitations and/or potential for further development of these agents as PCa therapies.
Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer.
TLDR
Compound 26f exhibited inhibitory and degradation effects in vitro in a wide array of wtAR, point mutant, and truncation mutant-driven prostate cancers (PCs) and inhibited tumor cell growth in a xenograft model composed of enzalutamide-resistant (EnzR) LNCaP cells.
...
1
2
...

References

SHOWING 1-10 OF 46 REFERENCES
Darolutamide (ODM-201) for the treatment of prostate cancer
  • N. Shore
  • Medicine, Biology
    Expert opinion on pharmacotherapy
  • 2017
TLDR
Darolutamide is an oral, investigational, high-affinity AR antagonist which has activity against known AR mutants that confer resistance to other second-generation antiandrogens, has minimal blood–brain barrier penetration, and does not significantly increase serum testosterone, which may offer potential advantages over the second- Generation antiandrogen.
Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer
TLDR
Except for the development of novel antiandrogens and CYP-17 modulators, bipolar androgen therapy is an interesting therapeutic approach and the combinations of the novel agents tested in Phase I and II studies with established agents is another field of interest.
ARN-509: a novel antiandrogen for prostate cancer treatment.
TLDR
ARS-509 exhibits characteristics predicting a higher therapeutic index with a greater potential to reach maximally efficacious doses in man than current AR antagonists, and offers preclinical proof of principle for ARN-509 as a promising therapeutic in bothCastration-sensitive and castration-resistant forms of prostate cancer.
Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC)
TLDR
The rationale for the newly approved hormonal treatments, their indications and complications, and the ongoing trials that are being done to improve the efficacy of the approved agents are presented.
Androgen receptor aberrations in the era of abiraterone and enzalutamide
TLDR
The most recent and relevant experimental findings on AR-signaling in castration-resistant prostate cancer are discussed in order to provide a comprehensive interpretation of the clinical behavior of this tumor entity following treatments with abiraterone, enzalutamide, ARN-509 or taxanes.
Apalutamide Treatment and Metastasis‐free Survival in Prostate Cancer
TLDR
Among men with nonmetastatic castration‐resistant prostate cancer, metastasis‐free survival and time to symptomatic progression were significantly longer with apalutamide than with placebo.
Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide
TLDR
The overall frequency of detected mutations at baseline and progression using the sensitive BEAMing assay was low, suggesting that, based on this assay, AR-LBD mutations such as F877L and T878A are not common contributors to de novo or acquired resistance to apalutamide.
Androgen receptor targeting drugs in castration‐resistant prostate cancer and mechanisms of resistance
TLDR
Promising therapies and novel biomarkers, such as AR‐V7, may lead to improved outcomes for CRPC patients and several novel agents may overcome resistance mechanisms.
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
TLDR
The diarylthiohydantoins RD162 and MDV3100 are characterized, two compounds optimized from a screen for nonsteroidal antiandrogens that retain activity in the setting of increased androgen receptor expression that appear to be promising candidates for treatment of advanced prostate cancer.
...
1
2
3
4
5
...